These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 8,659% surge in interest NuCana (NCNA),
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 8,659% surge in interest NuCana (NCNA),
Citi believes data from BioMarin’s (BMRN) ongoing CANOPY trial for the treatment of achondroplasia and other skeletal dysplasia at the International Skeletal Dysplasia Society meeting support Voxzogo’s treatment benefit for
Citi analyst David Lebowitz has maintained their neutral stance on BMRN stock, giving a Hold rating on September 17. David Lebowitz has given his Hold rating due to a combination
Barclays analyst Gena Wang maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of $110.00. The company’s shares closed yesterday at $71.14.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: NuCana (NCNA), 6,545% surge in interest BioMarin (BMRN), 707%